Liraglutide vs Dihexa
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
LiraglutideCognitive Enhancement
Dihexa- Summary
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Dihexa is a potent experimental oligopeptide derived from angiotensin IV that dramatically enhances synaptogenesis. Preclinical research shows cognitive enhancement orders of magnitude more potent than BDNF — it is considered one of the most powerful nootropic compounds in research, but has very limited human safety data.
- Half-Life
- ~13 hours (once-daily dosing)
- Unknown (limited pharmacokinetic data)
- Admin Route
- SubQ
- Oral, SubQ, Topical
- Research
- —
- —
- Typical Dose
- Start 0.6 mg, titrate to 3 mg
- 5–10 mg
- Frequency
- Once daily
- Daily
- Key Benefits
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Dramatically increases synapse formation (potentially 10 million× more potent than BDNF in animal models)
- Enhances memory and learning
- May reverse cognitive decline
- Improves neuroplasticity and executive function
- Long-lasting cognitive benefits from short courses
- Potential therapeutic agent for Alzheimer's
- Side Effects
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Headache
- Irritability
- Brain fog during washout period
- Unknown long-term effects (insufficient data)
- Stacks With
- —
- —